16 apr: Første ordre i Emiraterne
16 apr: Nordea Bank udsteder nye Mini Futures
16-04-2019 12:46:43

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2019

Company Announcement

  • Net sales of DARZALEX in the first quarter of 2019 totaled USD 629 million

  • Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc.

Copenhagen, Denmark; April 16, 2019 –

Genmab A/S (Nasdaq Copenhagen: GEN) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 629 million in the first quarter of 2019. Net sales were USD 352 million in the U.S. and USD 277 million in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.




DARZALEX® (daratumumab) injection for intravenous infusion is indicated in the United States in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma. DARZALEX is indicated in Europe in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S. In Japan, DARZALEX is approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma.  DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United Stated, Europe and Japan.  For more information, visit www.DARZALEX.com.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.  Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).1,2,3,4,5

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and frontline multiple myeloma settings and in amyloidosis.  Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases, such as NKT-cell lymphoma, B and T-ALL.  Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA, for multiple myeloma, as both a monotherapy and in combination with other therapies.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect®  platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.


Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

1 DARZALEX Prescribing information, February 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761036s016lbl.pdf Last accessed February 2019

2 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.

3 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.

4Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.

5Jansen, JH  et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. Blood. 2012; 120(21): abstract 2974.

Company Announcement no. 19

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V




Relateret indhold
19 jun - 
Genmab: Blackrock er tilbage i storaktionærklubben
12 jun - 
Genmab/Jyske: Forsinket godkendelse har øget risiko for..
11 jun - 
Tirsdagens aktier: Ambu og Novo toppede marked klædt i ..
Relateret debat
25 jun - 
Ja det begynder med M... .
25 jun - 
der sker jo hele tiden noget - er det noget specielt du..
25 jun - 
Så er Black Rock lige under de 5 % igen (4,97%). Bare r..

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 jun
Black Rock ligger lige nu med Ca 5% af alle Genmab aktier, de ligger og svinger på lige over og unde..
19 jun
God signalværdi
19 jun
Interessant 👍
19 jun
Nu over igen... Lad os håbe de har appetit på mange flere... Og at nogle shorts snart skal indløses...

Vestas indgår forlig med GE i patentsag: Betaler fortroligt beløb

25-06-2019 16:36:29
Vestas har indgået forlig med den amerikanske rival Generel Electric i forbindelse med flere patentsager. Det betyder, at sagerne nu droppes, oplyser de to selskaber i en meddelelse.Vestas betaler i forbindelse med forliget en fortrolig sum penge til GE. Derudover giver forliget en krydslicens til paterne, der omhandler teknologi, der bruges til at sikre stabiliteten i vindmøllerne under forstyrre..

Amerikanske medicinalvirksomheder slår sig sammen i millardhandel

Relaterede nyheder
25-06-2019 13:05:35
Den amerikanske medicinalvirksomhed Abbvie overtager sin kollega Allergan i en handel til en værdi af 63 mia. dollar.Det bekræfter de to selskaber, efter at Wall Street Journal tidligere tirsdag kunne citere kilder for, at opkøbet var på vej.Ifølge aftalen betaler Abbvie 188,24 dollar per aktie i Allergan, svarende til en præmie på 45 pct. sammenlignet med lukkekursen på Allergan mandag.Aktien i A..

Mærsk lancerer nyt onlineprodukt: Vil bryde med overbookinger

25-06-2019 10:36:22
(Korr: ændring i andet afsnit. Ordet "betales" er ændret til "aftales".)A.P. Møller-Mærsk lancerer et nyt onlineprodukt, der skal være med til at gøre transporten af containere mere simpel for kunderne, og som samtidig kan være med til at undgå overbookinger.Produktet går under navnet Maersk Spot, og det sikrer kunderne en garanti for, at fragten bliver lastet, skriver Mærsk i en pressemeddelelse ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
Britisk investeringsfirma reducerer shortposition i to danske aktier
Danske Bank/Nordea: Sænker kursmål med 10 kr.
Detektivfirma: Danske Bank fyrede os af frygt for hvidvasksag
Aktier/tendens: Inspirationen hælder mest til den negative side
Ørsted lægger to enheder sammen: Koncerndirektør forlader selskabet

Relaterede aktiekurser

Genmab A/S 1.188,50 -1,0% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
26. juni 2019 04:20:10
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB5 - 2019-06-26 04:20:10 - 2019-06-26 04:20:10 - 1 - Website: OKAY